TEVA.N Teva Pharmaceutical Industries Limited Sponsored ADR

Teva to Host Conference Call to Discuss Third Quarter 2024 Financial Results at 8 a.m. ET on November 6, 2024

Teva to Host Conference Call to Discuss Third Quarter 2024 Financial Results at 8 a.m. ET on November 6, 2024

TEL AVIV, Israel, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its financial results for the third quarter of 2024 on Wednesday, November 6, 2024, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET.

In order to participate, please register in advance  to obtain a local or toll-free phone number and your personal pin.

A live webcast of the call will be available on Teva's website at:

Following the conclusion of the call, a replay of the webcast will be available within 24 hours on Teva's website.

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a global pharmaceutical leader with a category-defying portfolio, harnessing our generics expertise and stepping up innovation to continue the momentum behind the discovery, delivery, and expanded development of modern medicine. For over 120 years, Teva's commitment to bettering health has never wavered. Today, the company’s global network of capabilities enables its ~37,000 employees across 58 markets to push the boundaries of scientific innovation and deliver quality medicines to help improve health outcomes of millions of patients every day. To learn more about how Teva is all in for better health, visit .

Cautionary Note Regarding Forward-Looking Statements

This press release and the conference call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully compete in the marketplace including our ability to successfully execute our Pivot to Growth strategy; our substantial indebtedness; our business and operations in general; compliance, regulatory and litigation matters; other financial and economic risks; and other factors discussed in this press release, in our Quarterly Report on Form 10-Q for the second quarter of 2024, and in our Annual Report on Form 10-K for the year ended December 31, 2023, including in the sections captioned "Risk Factors." Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

IR Contacts Ran Meir+1 (267) 468-4475
  Yael Ashman+972 (3) 914 8262
  Sanjeev Sharma+1 (973) 658 2700 
Media Contacts Kelley Dougherty



Eden Klein
+1 (973) 832-2810



+972 (3) 906 2645


EN
30/09/2024

Underlying

Reports on Teva Pharmaceutical Industries Limited Sponsored ADR

 PRESS RELEASE

Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (de...

Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab) Teva’s biosimilar, PONLIMSI™, is now FDA-approved across all indications of the reference product, Prolia® (denosumab), to treat a variety of debilitating bone conditions.Teva’s proposed biosimilar candidate to Xolair® (omalizumab) is accepted for review by U.S. FDA and EU EMA.These milestones demonstrate Teva’s biosimilars expertise and are a significant step in Teva’s Pivot to Growth strategy, highlighting its transformation into a...

 PRESS RELEASE

Teva gewinnt an Dynamik im Biosimilar-Geschäft mit der FDA-Zulassung f...

Teva gewinnt an Dynamik im Biosimilar-Geschäft mit der FDA-Zulassung für PONLIMSI™ (Denosumab-adet) und der Annahme von parallelen Zulassungsanträgen für einen Biosimilar-Kandidaten zu Xolair® (Omalizumab) Tevas Biosimilar PONLIMSI™ ist nun von der FDA für alle Indikationen des Referenzprodukts Prolia® (Denosumab) zur Behandlung verschiedener schwerer Knochenerkrankungen zugelassen.Tevas vorgeschlagener Biosimilar-Kandidat zu Xolair® (Omalizumab) wurde sowohl von der FDA als auch von der EMA zur Prüfung angenommen.Diese Meilensteine unterstreichen Tevas Expertise im Bereich der Biosimilars ...

 PRESS RELEASE

Teva gagne du terrain dans le domaine des médicaments biosimilaires gr...

Teva gagne du terrain dans le domaine des médicaments biosimilaires grâce à l’approbation accordée par la FDA pour PONLIMSI™ (dénosumab-adet) et à l’acceptation d’un double dossier pour un candidat biosimilaire à Xolair® (omalizumab) Le médicament biosimilaire de Teva, PONLIMSI™, est désormais approuvé par la FDA pour toutes les indications du produit de référence, Prolia® (dénosumab), dans le cadre du traitement de diverses pathologies osseuses invalidantes.Le candidat biosimilaire proposé par Teva pour le Xolair® (omalizumab) a été accepté en vue d’un examen par la FDA américaine et l’EMA...

 PRESS RELEASE

Teva gewinnt an Dynamik im Biosimilar-Geschäft mit der FDA-Zulassung f...

Teva gewinnt an Dynamik im Biosimilar-Geschäft mit der FDA-Zulassung für PONLIMSI™ (Denosumab-adet) und der Annahme von parallelen Zulassungsanträgen für einen Biosimilar-Kandidaten zu Xolair® (Omalizumab) Tevas Biosimilar PONLIMSI™ ist nun von der FDA für alle Indikationen des Referenzprodukts Prolia® (Denosumab) zur Behandlung verschiedener schwerer Knochenerkrankungen zugelassen.Tevas vorgeschlagener Biosimilar-Kandidat zu Xolair® (Omalizumab) wurde sowohl von der FDA als auch von der EMA zur Prüfung angenommen.Diese Meilensteine unterstreichen Tevas Expertise im Bereich der Biosimilars ...

 PRESS RELEASE

Teva gagne du terrain dans le domaine des médicaments biosimilaires gr...

Teva gagne du terrain dans le domaine des médicaments biosimilaires grâce à l’approbation accordée par la FDA pour PONLIMSI™ (dénosumab-adet) et à l’acceptation d’un double dossier pour un candidat biosimilaire à Xolair® (omalizumab) Le médicament biosimilaire de Teva, PONLIMSI™, est désormais approuvé par la FDA pour toutes les indications du produit de référence, Prolia® (dénosumab), dans le cadre du traitement de diverses pathologies osseuses invalidantes.Le candidat biosimilaire proposé par Teva pour le Xolair® (omalizumab) a été accepté en vue d’un examen par la FDA américaine et l’EMA...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch